Condition (MeSH)
Lymphoma, Large-Cell, Immunoblastic
ClinicalTrials.gov lists 490 trials for Lymphoma, Large-Cell, Immunoblastic or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 58.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase (log scale)
2 more sections with rows
490 of the 490 trials are tagged with Lymphoma, Large-Cell, Immunoblastic itself; the rest are tagged with a narrower condition beneath it.
When did Lymphoma, Large-Cell, Immunoblastic trials start? (27)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Phase 4
- Not applicable
- Observational
- Other (Expanded access, Unknown)
Top of scale: 49
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2016 | 1 |
| 2015 | 2 |
| 2014 | 6 |
| 2013 | 7 |
| 2012 | 7 |
| 2011 | 8 |
| 2010 | 16 |
| 2009 | 18 |
| 2008 | 27 |
| 2007 | 33 |
Showing 10 of 27 earlier years.
No forecast is made for this condition: it averages 0.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: none of the 490 trials evaluated at the 2026-10-09 snapshot is predicted and still running. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Lymphoma, Large-Cell, Immunoblastic trials in? (10)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 163 |
| Phase 1/2 | 41 |
| Phase 2 | 153 |
| Phase 2/3 | 2 |
| Phase 3 | 48 |
| Phase 4 | 1 |
| Not applicable | 47 |
| Observational | 33 |
| Expanded access | 1 |
| Unknown | 1 |
How many Lymphoma, Large-Cell, Immunoblastic trials are recruiting? (7)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 2 |
| Active, not recruiting | 4 |
| Completed | 366 |
| Terminated | 65 |
| Withdrawn | 21 |
Showing 5 of 7 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Lymphoma, Large-Cell, Immunoblastic trials? (2)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| National Cancer Institute (NCI) | 58 |
| National Institutes of Health Clinical Center (CC) | 13 |
Which drugs are being tested for Lymphoma, Large-Cell, Immunoblastic? (4)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| Cytoxan | 115 |
| RITUXIMAB | 56 |
| Busulfan | 44 |
| Melphalan | 40 |
Interventions as named in the registry (11)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| Peripheral blood stem cell transplantation | 96 |
| Filgrastime (G-CSF) | 72 |
| Etoposid | 69 |
| SQ Fludarabine | 62 |
| Radiation Therapy | 56 |
Showing 5 of 11 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Lymphoma, Large-Cell, Immunoblastic trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Death | 243 | 13 |
| unplanned hospitalisation (emergency case) | 112 | 1 |
| 1 yr TRM | 93 | 1 |
| Febrile neutropenia | 65 | 13 |
| Regimen Related Toxicity | 63 | 1 |
Showing 5 of 10 adverse events.
Which publications cover Lymphoma, Large-Cell, Immunoblastic? (5)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| Angio-immunoblastic T cell lymphoma (AILD-TL) rich in large B cells and associated with Epstein-Barr virus infection. A different subtype of AILD-TL? | Leukemia | 2002 | Yes |
| Lenalidomide in combination with vorinostat and dexamethasone for the treatment of relapsed/refractory peripheral T cell lymphoma (PTCL): report of a phase I/II trial. | Annals of hematology | 2014 | No |
| Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. | Journal of clinical oncology : official journal of the American Society of Clinical Oncology | 2001 | No |
| Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. | Blood | 1996 | No |
| AIDS-associated non-Hodgkin lymphoma. | Lancet (London, England) | 1991 | No |
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.